» Pharmacolog increases market focus with issue
» BioStock Investor Meeting: Idogen presents
» BioStock Investor Meeting: Elicera Therapeutics presents
» BioStock Investor Meeting: Cyxone presents
» Positive results from Respiratorius PK study
Read BioStock's newsletter for v.37 here.
Morning news
BrainCool have received orders for two BrainCool System i Vietnam. Read more.
Idogen's cell therapy for hemophilia, ItolDC-028, described in the scientific journal Hemophilia. Read more.
Sensidose participated in Polish Neurological Society congress on September 14-17 in Lublin. Read more.
Corline Biomedical announces clinical data from Renapair 01. Read more.
Azstra Zenecas evusheld has received EU approval for the treatment of covid-19. Read more.
Helena Strigård is the new CEO of NorthX Biologics. Read more.
Bavarian Nordic announces contract for the supply of smallpox and monkeypox vaccines to Canada. Read more.
First results from Photocures Clinical Laser III study has been published. Read more.
XVI has been granted Breakthrough Device Designation from FDA. Read more.
Elekta announces orders for Versa HD linac system from Karkinos Healthcare. Read more.
Faron Pharmaceuticals announces top-line data regarding Bexmarilimab. Read more.
Company presentations:
Allarity Therapeutics NeoDynamics Qlife Redwood Pharma Targovax
Changes in equity and number of votes:
Invitations:
Communiqués:
Bioservo Technologies Orphazyme
News since Monday lunch
Aptahem has submitted a regulatory application to initiate a phase I clinical study with Apta-1. Read more.
Cyxone receives regulatory approval to start clinical phase IIb study in RA. Read more.
Respirator has announced the distribution of the acquisition cost regarding share dividends in Arcede Pharma. Read more.
Alligator Bioscience and Aptevo Therapeutics has announced that FDA given the go-ahead to begin clinical studies with ALG.APV-527. Read more
Hakan Engqvist has been appointed as the new CEO of Emplicure. Read moreThe company has also announced that it is implementing a holding company structure. Read more.
Lumitos product SCIZYS and new tissue images were presented at ECP. Read more.
Stock analysis of Stayble Therapeutics has been published by Kalqyl. Read more.
Inhalation Sciences presents results from PreciseInhale clinical study at DDL 2022. Read more.
MSD has received a positive CHMP opinion for Waxneuvance. Read more.
galderma has announced data from a phase III study with nemolizumab. Read more.
In study at Medclairs nitrous oxide technology has been published in Anaesthesia Reports. Read more.
CS Medica preparing for listing on Nasdaq Main Market in Denmark. Read more.
Brighter has published a supplementary prospectus. Read more.
Prostatype Genomics together with KI has carried out a comprehensive validation process with Prostatype. Read more.
SpectraCures new generation of treatment systems has been approved by MHRA. Read more.
Flagging in Ecti Research has been issued. Read more.
Zealand Pharma presented data from phase III study at espe. Read more.
Xbrane Biopharma invites you to Capital Markets Day. Read more.
Outcome of Learning to Sleep TO2 warrants have been announced. Read more.
Biohit announces scientific support for GastroPanel i International Maastricht/Florence Consensus Report. Read more.
NanoEcho has been granted 200 SEK from Vinnova. Read more.
This morning's price development
Winner: Asarina Pharma 17,6%, RhoVac 11,1%, Prostatype Genomics 10,6%, Fluicell 9,7%, S2Medical 9,5%
Förlorare: Brighter -12,6%, Zenicor -12,4%, Double Bond Pharmaceutical -12,2%, Lumito -11,9%, NeoDynamics -9,6%
Index: OMXS30 0,23% 1882 , Healthcare -0,42
More articles from BioStock
» Attention for mito patients during WMDW
» BioStock Investor Meeting: Cereno Scientific presents
» BioStock Investor Meeting: Pharmiva presents
» Pharmacolog's CEO on issuance and market growth
» PolarCool's CEO sees increased demand for PolarCap